NCIt definition : An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal
growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic
activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2,
which may result in the inhibition of tumor growth and angiogenesis, and tumor regression
in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing
tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases
overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation
and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier
(BBB) and does not appear to be a substrate for efflux pumps.;
UNII : 70CCB438L6;
CAS number : 871026-44-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 871026-44-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;